# A Study of LM-24C5 For Advanced Solid Tumors

Source: https://onco.cc/trials/nct06187402/  
OnCo record `nct06187402` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

A Study of LM-24C5 For Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06187402 by LaNova Medicines Limited, with 49 participants planned, started 2023-12-20 and due to reach its primary completion in 2026-06-30. Interventions recorded: LM-24C5.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06187402
- Phase: 1/2
- Setting: A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors
- Sponsor: LaNova Medicines Limited
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT06187402: https://clinicaltrials.gov/study/NCT06187402

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06187402.json